Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.58 |
| ▸ | ITGAV | P06756 | 4/20 | 0.58 |
| ▸ | SYK | P43405 | 8/20 | 0.51 |
| ▸ | RHOA | P61586 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878294 | 0.75 | ITGB3 (0.73) | ITGB3ITGAVTTK | |
| SCHEMBL17006499 | 0.67 | SYK (1.00) | SYK | |
| SCHEMBL5127211 | 0.67 | CYP26B1 (0.54) | FFAR1HTR6 | |
| SCHEMBL23455427 | 0.67 | AKR1C3 (0.59) | SYKRHOA | |
| SCHEMBL30073959 | 0.67 | AKR1C3 (0.59) | SYKRHOA | |
| SCHEMBL4428876 | 0.65 | ABCC4 (0.51) | NAMPTFFAR1HTR6 | |
| SCHEMBL5068799 | 0.65 | CA1 (0.65) | FFAR1HTR6 | |
| SCHEMBL13667982 | 0.65 | KEAP1 (0.53) | FFAR1HTR6FFAR4 | |
| SCHEMBL29780326 | 0.64 | RHOA (0.58) | ITGB3SYKRHOAFFAR1SIRT1 | |
| SCHEMBL7347912 | 0.64 | FFAR1 (0.69) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | ITGB3 3/4885ITGAV 13/4885SYK 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.